Generation and inhibition of activated factor IXa was studied in factor Xla-activated plasma containing 4 mmol/L free calcium ions and 20 pmol/L phospholipid (25 mol% phosphatidylserine/75 mol% phosphatidylcholine). Interference of other (activated) clotting factors with the factor IXa activity measurements could be avoided by using a highly specific and sensitive bioassay. Factor IXa generation curves were analyzed according t o a model that assumed Michaelis-Menten kinetics of factor Xla-catalyzed factor IXa formation and pseudo first order kinetics of inhibition of factor Xla and factor IXa. In the absence of heparin, factor IXa activity in plasma reached final levels that were found t o increase with increasing amounts of factor Xla used t o activate the plasma. When the model was fitted t o this set of factor IXa generation curves, the analysis yielded a rate constant of inhibition of factor Xla of 0.7 k 0.1 min-' and a k,,/K, ratio of 0.29 k 0.01 (nmol/L)-' min-'. No neutralization of factor IXa activity was observed (the estimated rate constant of inhibition of ACTOR IX can be activated via both the intrinsic and F extrinsic coagulation pathways. Thus, it forms a link between these pathways that is thought to be of crucial importance for the initiation phase of blood coagulation. ' The majority of studies on the regulation of factor IXa by plasma proteinase inhibitors have been done with purified enzyme either in plasma or It has been shown that bovine and human factor IXa react slowly with antithrombin 111, but do not react with a,-macroglobulin and a,-proteinase
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The reaction with antithrombin I11 is greatly stimulated by the presence of heparin. Similar to the mechanism of thrombin inhibition, the simultaneous binding of both the inhibitor and enzyme to the same heparin molecule seems to be required for maximal rates of inactivation of factor IXa.3.6.7 For bovine factor IXa it was found that pentasaccharide did not stimulate the proteinase/antithrombin I11 r e a~t i o n .~ But, while calcium ions inhibit the thrombin/ antithrombin III/heparin reaction, they greatly stimulated the bovine factor IXa/antithrombin III/heparin rea~tion.~. ' In addition to these studies, two groups have reported on the effects of heparin on the progress of activation of radiolabeled factor IX in contact-activated plasma and in thromboplastin-activated
In the latter case, 5 U/mL of heparin almost completely blocked factor IX activation. During contact activation, heparin did not significantly affect the steps preceding factor X activation. That is, in the absence or presence of 0.5 U/mL heparin, the extent of radiolabeled factor IX cleavages a t 30 minutes was essentially identical. Factor IXa activity levels were reduced in the presence of heparin, but were still found to be significantly higher than was required for factor X activation to occur in the absence of heparin. We note that under these conditions, heparin-dependent inhibition of factor VIIIa formation, as a result of the anti-thrombin activity of heparin," is likely to cause the inhibition of factor Xa generation rather than the heparin-dependent neutralization of factor IXa activity.
factor IXa was 0). Thus, in the absence of heparin, the final level of factor IXa in plasma is only dependent on the initial factor Xla concentration. While neutralization of in situ generated factor IXa in normal plasma was negligible, unfractionated heparin dramatically enhanced the rate of inactivation of factor IXa (apparent second order rate constant of inhibition of 5.2 min-'/per pg heparin/mL). The synthetic pentasaccharide heparin, the smallest heparin chain capable of binding antithrombin 111, stimulated the inhibition of in situ generated factor IXa, but sevenfold less than unfractionated heparin (k = 0.76 min-' per pg pentasaccharide/mL). We found that free calcium ions were absolutely required t o observe an unfractionated heparin and pentasaccharide-stimulated neutralization of factor IXa activity. Factor Xla inhibition (pseudo first order rate constant of 0.7 min-') was not affected by unfractionated heparin or pentasaccharide in the range of heparin concentrations studied. However, a straightforward analysis of the generation and inhibition of factor IXa activity in heparinized plasma on the basis of a model that describes the time course of factor IXa generation and decay is currently not available. One of the difficulties might be the problem of measuring in situ generated factor IXa activity without interference by other activated coagulation factors formed.
The present study was undertaken to examine the effects of two types of heparin, ie, unfractionated heparin and a synthetic ultra low molecular weight heparin with high affinity for antithrombin I11 (pentasaccharide), on factor XIa-catalyzed factor IXa generation, and its inactivation in plasma. A highly specific factor IXa assay was used to monitor factor IXa activity generated in plasma.
MATERIALS AND METHODS
The synthetic peptide substrate Bz-Ile-Glu-(piperidy1)-Gly-Arg-p nitro-anilide hydrochloride (S-2337) was purchased from AB Kabi Diagnostica (Stockholm, Sweden). Factor IX deficient plasma was purchased from DiaMed AG (Morat, Switzerland Phospholipid vesicles were made from a mixture of phosphatidylserine (PS) and phosphatidylcholine (PC) as previously described.', Vesicles composed of 25 mol% PS and 75 mol% PC were used throughout this study.
Blood from healthy donors was collected on 0.13 mol/L trisodium citrate; nine parts of blood to one part of citrate solution. The blood was then centrifugated twice at room temperature for 15 minutes at 3,OOOg. A third centrifugation was done at 4OC for 1 hour at 23,OOOg. The obtained platelet-free plasma was stored at -8OOC.
To follow the activation of factor IX by factor XIa, an assay was developed in which factor IXa was determined via its ability to activate factor X in the presence of Ca2+ ions, phospholipid, and factor VIIIa. Briefly, factor IXa containing sample (10 pL) was added to 35 pL of Tris-buffer pH 7.9 (50 mmol/L Tris-HCI, 175 mmol/L NaC1, 0.5 mg ovalbumin/mL) containing CaCI, (5 mmol/L), phospholipid (20 pmol/L), bovine factor VI11 (10 U/mL), and bovine factor X (0.5 pmol/L). Factor X activation was started by the addition of 10 pL of a thrombin solution (1 pmol/L) and the reaction was allowed to proceed for 90 seconds, after which 450 pL of Tris-buffer containing 20 mmol/L EDTA and 0.22 mmol/L S-2337 was added to stop the reaction and determine the amount of factor Xa formed as described previ~usly.~ From the observed rate of factor Xa formation, the amount of factor IXa present in the sample was calculated using a calibration curve made with known amounts of human factor IXa as determined by titration with antithrombin III/heparin.
Tris-buffer with or without heparin, 23 pL, or pentasaccharide, was added to 160 pL of citrated human plasma and incubated for 4 minutes in a flat-bottom plastic tube while stirring. Phospholipids were also added to a final concentration of 20 pmol/L. The plasma was activated by the addition of CaCI, (20 mmol/L) and factor XIa at the concentrations indicated. The free Ca2+ concentration (4 mmol/L) was measured using a calcium-specific electrode (Radiometer, Copenhagen, Denmark) standardized with CaC1, in Tris buffer. Timed samples (5 pL) were removed from the incubations, diluted 200-fold in ice-cold Tris buffer and assayed for factor IXa activity.
The analysis of the factor IXa generation curves in the presence of proteinase inhibitors was based on the following assumptions: factor IX activation by factor XIa follows Michaelis-Menten kinetics, and inactivation of factor IXa and factor XIa can both be described as simple pseudo first order reactions.
When the actual concentration of factor IX at time t is [IXa] is the concentration of free factor IXa at timet, [IX] , is the factor IX concentration at t = 0 and [IXa.I] is the concentration of factor IXa-inhibitor complex at time t, then the factor IXa generation curves can be described by the following set of differential equations:
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where k,,, and k,,, are the pseudo first order rate constants of inhibition of factors XIa and IXa, respectively. The initial conditions are: [XIa] , is the amount of factor XIa added to the plasma, with both [IXa], and [IXa.I], zero at t = 0. The values for k,,,/K,, k,,,, and k,,, were estimated by a least squares fit of the numerical s o l u t i~n '~ of equations 1 through 3 to the experimentally determined factor IXa generation curve, using an iterative Gauss-Newton algorithm.I6
The reported errors represent the 95% confidence interval of the parameters as estimated by linearization of the nonlinear equations at the obtained parameter values.'7
RESULTS AND DISCUSSION
Factor IXa bioassay. W e developed an assay for activated factor IX based on the formation of a highly efficient factor X converting complex that consists of factor IXa, phospholipids, Ca2+, and activated factor VIII. Under the assay conditions used, factor IXa is the rate-limiting factor and factor Xa generation is linear in time. Thus, the amount of factor Xa generated, measured as amidolytic activity toward S-2337, is proportional with the amount of factor IXa. Figure 1 shows the calibration curve constructed from known amounts of human factor IXa. Factor IXa concentration in the sample is plotted versus the rate of factor Xa formation. Because plasma contains approximately 80 nmol/ L of factor I x 9 factor IXa concentrations as low as 1% of total factor IX can be detected.
A number of control experiments were performed to establish that our factor IXa bioassay was suited to monitor factor IXa generation in clotting plasma. Purified human factor IX (70 nmol/L) was added to congenital factor IX deficient plasma (less than 1% factor IX), followed by the addition of purified human factor XIa ( 5 nmol/L), 20 Fmol/L phospholipid, and CaCI, to a concentration of 4 mmol/L free Ca2+. Although phospholipids are not required for the factor XIa-catalyzed factor IX activation reaction,'* they were included to let the process of clotting proceed via factor Xa and thrombin generation into fibrin formation. The plasma clotting time was 120 seconds. A t timed intervals, samples were taken from the activated plasma and immediately diluted. A 200-fold dilution was sufficient to stop further factor IXa generation and inactivation. As shown in recovered as activated factor IX. Interestingly, inhibition of activated factor IX was not observed. As a control on the effects of endogenously generated factor Xa and thrombin on the factor IXa assay, factor IX deficient plasma was activated with thromboplastin. Although the plasma clotted at 45 seconds and peak values for factor Xa and thrombin were 10 nmol/L and 360 nmol/L, respectively, baseline values for the factor IXa assay were obtained. Thus, because of the 1,000-fold dilution of the plasma sample into the assay mixture, endogenous formed factor Xa and thrombin did not interfere with the factor IXa assay. Furthermore, the dilution was sufficient to avoid influence of carried-over antithrombin 111 (-2 nmol/L) and heparin on the rate of factor Xa formation, and thus factor IXa determination.
Factor ZXa generation in plasma at varying amounts of factor XZa. We first studied plasma factor IXa generation as a function of the factor XIa concentration. We already noted that factor IXa activity was not neutralized when generated in factor XIa-activated plasma. Figure 3 clearly shows that on the addition of factor XIa to plasma, plateau levels of factor IXa activity were reached. This finding contrasts with the second-order rate constant of inhibition of purified human factor IXa by antithrombin 111 as reported by Jordan et al.3 At the plasma concentration of antithrombin 111 (2.5 Mmol/L) one might expect a half-life time of factor IXa activity of about 10 minutes. However, the failure to demonstrate decay of endogenous factor IXa in plasma is in accordance with the observation of McNeely and Griffith,' who found that 5% of radiolabeled factor IXa appeared to be complexed with antithrombin I11 after 30 minutes of incubation of radiolabeled factor IX in contact-activated plasma. The plateau level of factor IXa activity increased with increasing amounts of factor XIa added to the plasma. Apparently, plasma inhibitors neutralize factor XIa activity at such a rate that at relatively low factor XIa concentrations complete neutralization of factor XIa is achieved before all plasma factor IX is converted into factor IXa. More than 5 nmol/L factor XIa was needed to obtain a factor IXa concentration in plasma that approached its proenzyme concentration. Estimation of a global apparent rate constant of inhibition of factor XIa in plasma was obtained by fitting the model described in Materials and Methods to the set of factor IXa generation curves shown in Fig 3. Because inhibition of factor IXa was not observed, the pseudo first order rate constant of inhibition of factor IXa was held constant at a value of zero. The ratio LJK, and pseudo first order rate constant of inhibition of factor XIa were the adjustable parameters of the model. It is clear that our model (solid lines) fits well to the experimental factor IXa generation curves. The residuals of the curves fitted to the experimental data varied randomly around 0 and were smaller than 2%.
The estimated value of the kJKm ratio was 0.29 + 0.01 (nmol/L)-l min-I. This value is in good agreement with those reported by Walsh et all9 and our laboratory'' for factor XIa-catalyzed factor IX activation in purified systems, 0.47 and 0.23 (nmol/L)-l min-I, respectively. The rate constants of inhibition of factor XIa as calculated from each of the factor IXa generation curves varied between 0.9 and 0.6 minutes ( Table 1) . These values are in good agreement with the value that can be calculated from the data reported by Scott et a1." Taking their second-order rate constants of inhibition of factor XIa by various proteinase inhibitors determined at 37°C and the plasma concentrations of these inhibitors, one can predict a pseudo first-order rate constant of factor XIa decay in undiluted plasma of 0.86 min-'. In our experiments the final plasma dilution of whole plasma was 80%.
The heparin-stimulated neutralization of in situ generated factor IXa. The effects of the Fourth International pmol/L phospholipid. Whereas the quality of the fit of the mathematical model to the factor IXa activity data obtained in the absence of heparin appears to be quite acceptable (Fig  3) , it was not in the presence of heparin. At the decay phase following the plasma clotting time large deviations between the experimental generation curve and the computed one were found. This finding indicates that the factor IXa decay becomes much slower once the plasma clots. Possible explanations for this penomenon are consumption of antithrombin I11 caused by the generation of large amounts of thrombin (-1.0 pmol/L) and/or protection by fibrin monomers of factor IXa from inactivation by heparin-antithrombin 111, as recently has been reported for thrombin.*' To compare the heparin-stimulated inhibition of in situ generated factor IXa before and after fibrin formation, the following experiments were performed. Plasma was incubated with factor XIa (2 nmol/L), Ca2+, and phospholipid as described in Materials and Methods. At the time point (4 minutes) when factor IXa activity reached a final level, ISH (0.18 pg/mL) was added and the rate of neutralization of factor IXa activity was determined as shown in Fig 4. Under these conditions, the decay of factor IXa activity was measured after clot formation (clotting time was 150 seconds). To examine factor IXa decay before the clotting time of plasma, it is necessary either to stop further factor IXa generation or to lengthen the clotting time of plasma until factor IX activation and subsequent neutralization of factor IXa is completed. Because calcium ions are essential to the activation of factor IX by factor XIa, further factor IXa formation could be blocked at any time by the addition of EDTA to the plasma. When heparin is added at the same time, the rate constant of inhibition of factor IXa can then be determined before the plasma clots. However, EDTA completely abolished the heparin-stimulated inactivation of factor IXa. indicating that calcium ions are essential to the heparin-stimulated reaction between human factor IXa and human antithrombin I11 (data not shown). The same finding for the bovine factor IXa-heparin/AT I11 reaction has previously been reported by our group. ' Therefore, to study the heparin-stimulated inhibition of factor IXa in nonclotted plasma, the clotting time of plasma had to be lengthened. In the presence of hirudin (0.25 pmol/L), the clotting time was 8 minutes, so that when heparin (0.18 pg/mL) was added 4 minutes after factor XIa, the decay phase of factor IXa activity could be studied without further factor IXa generation and before the plasma clotted. Figure 4 shows that factor IXa generation in factor XIa-activated plasma is not affected by hirudin. The very same levels of factor IXa activity were obtained whether hirudin was present or not. The heparin-stimulated rate of inhibition of in situ generated factor IXa was indeed faster before the clotting time of plasma than after it. Addition of 1.0 pmol/L of purified human antithrombin I11 to the clotted plasma did not significantly enhance the rate of the heparinstimulated inhibition of factor IXa, indicating that consumption of antithrombin I11 did not lower the rate of the heparin-stimulated inhibition of factor IXa.
The reduced rate of factor IXa inhibition was also observed when clot formation was induced by factor Xa (10 nmol/L) in factor VI11 deficient plasma, indicating that the possibility of protection of factor IXa from inhibition by antithrombin III/heparin as a result of complex formation with factor VIIIa and phospholipid could be ruled out (data not shown). Whether fibrinogen degradation products and/ or, as recently demonstrated for heparin-stimulated inactivation of thrombin,21 fibrin monomer protects factor IXa from inactivation by heparin-antithrombin I11 remains to be established.
Factor IXa neutralization studies in the presence of hirudin (0.5 pmol/L), using the approach shown in Fig 4, were then performed to determine the pseudo first order rate constant of inhibition of in situ generated factor IXa as a function of the amount of ISH and that of synthetic pentasaccharide heparin. The amount of hirudin was sufficient to prolong the clotting time from 2.5 minutes to more than 10 minutes and was not found to influence the factor XIa-catalyzed factor IX activation in plasma. Table 2 lists the pseudo first order rate constants of inhibition of endogenous factor IXa as determined in factor XIa-activated plasma containing varying amounts of ISH or pentasaccharide. From the linear dependency between the rate constant and the amount of heparin, rate constants of 5.2 min-' per pg ISH/mL and 0.76 min-' per pg pentasaccharide/mL were calculated. Thus, on a weight basis, ISH was seven fold more active than pentasaccharide in its stimulation of the factor IXa-antithrombin 111 reaction. On a molar basis, ISH (mean molecular weight [mol wt] = 14,000 and 40% antithrombin I11 high affinity material) is about 140-fold more active than pentasaccharide (mol wt = 1,700). Although little is known about the interaction of factor IXa-heparin-antithrombin 111, it is generally assumed that the mechanism of factor IXa inhibition resembles that of That is, binding of antithrombin 111 and factor IXa to the same heparin molecule is required for rapid inactivation of factor IXa. Therefore, heparin fragments below mol wt = 5,000 (1 8 saccharides) are believed to be of insufficient length to potentiate the inhibition of factor IXa.6 Therefore, the stimulation of the factor IXa/antithrombin I11 reaction by pentasaccharide, which exerts its catalytic activity solely through a binding-induced conformational change in antithrombin 111,'' is an interesting observation. It indicates that the so-called approximation effect is less important for factor IXa inhibition than it is for thrombin inhibition. Effect of heparin on factor Xla-induced factor IXa generation in plasma. Next we examined the effects of the Fourth ISH and pentasaccharide on the pseudo first order rate constant of inhibition of factor XIa during factor IX activation. To this end, plasma was activated with factor XIa in the presence of varying amounts of ISH (Fig 5) and in the presence of varying amounts of pentasaccharide (Fig 6) . Each set of factor IXa generation curves thus obtained was analyzed by fitting the model described in Materials and
Time, min Methods to the experimental data points. In fitting the generation curves, the pseudo first order rate constant of inhibition of factor IXa was held constant at a value corresponding to the respective heparin concentration used, and independently determined as described in the previous section ( Table 2 ). The fitted parameters thus obtained were the pseudo first order rate constant of inhibition of factor XIa and the k,,/K, ratio. We conclude that at the heparin concentrations used, ISH and pentasaccharide did not stimulate the inactivation of factor XIa in plasma (Table 2) . Thus, although it has been reported that heparin with high affinity for antithrombin I11 at an amount of 1 U/mL markedly enhanced the rate of factor XIa inactivation by antithrombin I11 and C1-inhibitor in plasma," this was not observed a t heparin concentrations in the therapeutic range of about 0.1 U/mL of unfractionated heparin.
The fitted k,,/K, ratios corresponding to the set of curves obtained from the set of generation curves at different factor XIa concentrations in the absence of heparin (Fig 3) . As judged from the "goodness of fit," we conclude that factor XIa-induced factor IXa generation in plasma can be acceptably described by a mathematical model that assumes Michaelis-Menten kinetics of factor XIa-catalyzed factor IX activation in plasma and pseudo first order kinetics of the reactions between plasma inhibitors and factor XIa and factor IXa. Our data suggest that when plasma coagulation is started by factor XIa and heparin is present, the area under the factor IXa generation curve is dependent on the rate of inhibition of factor IXa, and thus on the amount of heparin present. The very same might be true when factor IX is activated by the factor VII(a)/tissue factor complex, because the activity of the complex is also poorly inhibited, if a t all, by heparin/antithrombin 111. However, it is still an open question whether the anti-factor IXa activity of unfractionated heparin, and also that of pentasaccharide, contrib-
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Utes significantly to the overall anticoagulant effect. It is interesting that already small amounts of unfractionated heparin (around 0.05 U/mL) dramatically reduce the total area under the factor IXa generation curve. Because the lag phase of factor VI11 activation is markedly affected by heparin, reduction of the area under the factor IXa generation curve might contribute to the anticoagulant activity of heparin because less factor IXa is available to form the physiologically important factor X activating complex at the time factor VIIIa is generated.
